 |
|
A new chemotherapeutic target for hepatocellular carcinoma
October 25, 2007Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation. However, many HCCs with scattered tumors cannot be operated on. In such patients, effective alternative therapies need to be discovered in order to treat patients in the early stages of this disease.
An article to be published on 28 October in the World Journal of Gastroenterology proposes a new target for therapy. A study was conducted by Dr. Satoshi Mamori, of Jikei University, in which he evaluated tumor biopsies in order to confirm the diagnosis of HCC.
The immunohistochemical expression of survivin in liver tumor specimens obtained from 17 patients was studied. In addition, to determine the survivin expression in response to anti-cancer drugs in early stage HCC, the survivin expression was determined after treating HCC cells with anti-cancer drugs under hypoxic culture conditions.
Survivin is a member of a family of inhibitors of apoptosis protein (IAP), which has been implicated in both the control of cell division and the inhibition of apoptosis. Survivin is selectively expressed in most common human neoplasms and it also appears to be involved in tumor cell resistance to some anticancer agents and ionizing radiation. Several preclinical studies have demonstrated a down-regulation of the survivin expression/function by the use of anti-sense oligonucleotide, dominant negative mutants, ribozymes, small interfering RNAs and cyclin-dependent kinase inhibitors to increase the rate of apoptosis, while also reducing the tumor growth potential and sensitized tumor cells to various chemotherapeutic drugs and ƒ×-irradiation using both in vitro and in vivo models of various types of human tumors.
The results and conclusions demonstrated survivin protein to be expressed in 64.7% of the cells in early HCC specimens (median). In early stage HCC with a tumor size > 10 mm, the expression rate ranged for 67.7 to 83.7%. Moreover, the survivin protein concentration in HCC cells increased with a combination of hypoxia and anti cancer drugs. With TACE, the conditions of hypoxia are maintained by embolisation over a long period of time. Therefore, this study suggests that survivin could be used as a potential useful therapeutic target for early HCC.
World Journal of Gastroenterology
Survivin is a member of a family of inhibitors of apoptosis protein (IAP), which has been implicated in both the control of cell division and the inhibition of apoptosis. Survivin is selectively expressed in most common human neoplasms and it also appears to be involved in tumor cell resistance to some anticancer agents and ionizing radiation. Several preclinical studies have demonstrated a down-regulation of the survivin expression/function by the use of anti-sense oligonucleotide, dominant negative mutants, ribozymes, small interfering RNAs and cyclin-dependent kinase inhibitors to increase the rate of apoptosis, while also reducing the tumor growth potential and sensitized tumor cells to various chemotherapeutic drugs and ƒ×-irradiation using both in vitro and in vivo models of various types of human tumors.
The results and conclusions demonstrated survivin protein to be expressed in 64.7% of the cells in early HCC specimens (median). In early stage HCC with a tumor size > 10 mm, the expression rate ranged for 67.7 to 83.7%. Moreover, the survivin protein concentration in HCC cells increased with a combination of hypoxia and anti cancer drugs. With TACE, the conditions of hypoxia are maintained by embolisation over a long period of time. Therefore, this study suggests that survivin could be used as a potential useful therapeutic target for early HCC.
World Journal of Gastroenterology
Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News RSSPromising novel treatment for human cancer -- Chrysanthemum indicum extract
A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects.
M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.
HBV genotype B/B3 and C/C1 are the major genotypes in Indonesia?
Previous studies revealed that HBV genotypes as well as mutations in the core promoter, precore or HBx gene have been shown to have an association with the clinical outcome of liver disease, however, this is still controversial.
Sequential TACE and cryosurgery can improve survival times for patients with HCC?
Hepatocellular carcinoma (HCC)--a liver cancer--is recognized as one of the most common cancers in the world that disproportionately affects Southeast Asians and Africans.
Is RTA a new potential option for the treatment of hydatid cysts?
Current treatment of cystic echinococcosis is surgery or percutaneous aspiration, injection and reaspiration (PAIR) using hypertonic saline or ethanol.
Targeting Tumor Behavior May Lead To New Liver Cancer Drugs
Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior.
What is the relationship between hepatocellular carcinoma and type 2 diabetes mellitus?
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths.
Low-fat diet helps genetically predisposed animals avoid liver cancer
In a study comparing two strains of mice, one susceptible to developing cancer and the other not, researchers found that a high-fat diet predisposed the cancer-susceptible strain to liver cancer, and that by switching to a low-fat diet early in the experiment, the same high-risk mice avoided the malignancy.
Study indicates cancer preventive effect for statins
The commonly used prescription statin drugs may have a protective effect in the prevention of liver cancer and lead to a reduction in the need for gallbladder removals, according to two studies published in Gastroenterologyiption statin drugs may have a protective effect in the prevention of liver cancer and lead to a reduction in the need for gallbladder removals, according to two studies published in Gastroenterology.
Is telmisartan effective in treating non-alcoholic steatohepatitis?
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.
More Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News Articles
 |
Hepatocellular Carcinoma by W. Y. Lau (Author), W. Y. Lau (Editor) This essential book is a compendium of papers written by an international team of world-renowned experts, who cover topics in their respective areas of expertise. Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics -- including those more controversial ones -- in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross pathology, from screening to atypical presentation, from diagnosis to treatment, and from assessment to choice of appropriate treatment. This volume is therefore an important contribution to the field of hepatocellular carcinoma. Contents: Epidemiology (T Y-M Leong & A S-Y Leong); Assessment of Liver Function (D V Mann); Prevention (M C Kew); Screening (M Sherman); Tumor Markers (J Y H... |
|
Surgsat: Professional Video Journal in General Surgery Volume II: 11:21 Liver Resection for Hepatocellular Carcinoma, 11:22 Operative Treatment of Cancer of the Colon, 11:23-24 The Technique of Total Thyroidectomy c1986 Video tape. John L. Cameron, M.D., editor. The John Hopkins Medical Institutions. CME-SAT. | |
 |
5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences - 2007- DVD1 Also With: The University of Texas - MD Anderson Cancer Center (Host) DVD 01- Treatment of HCC Yesterday and Today Surgery for HCC: an Eastern Perspective M. Makuuchi, MD Surgery for HCC: a Western Perspective J. Belgheti, MD Interstitial Therapy for HCC T. Livraghi, MD |
 |
Hepatocellular Carcinoma: Diagnosis and Treatment (Current Clinical Oncology) by Brian I. Carr (Editor) Hepatocellular cancer is the fifth most common cancer, with 600,000 new cases reported each year worldwide. Additionally, exciting changes in the science of HCC in the last four years have turned the practice of diagnosing and treating the disease upside down. In Hepatocellular Carcinoma: Diagnosis and Treatment, Second Edition, the leading experts in the field of HCC thoroughly update and expand upon the critically acclaimed first edition with all the latest developments in the diagnosis and treatment of primary liver cancer. The book details for physicians the diagnostic and therapeutic decision making process for dealing with such problems as incidental tumors in the liver transplant, the role of neo-adjuvant chemotherapy, intra-arterial vs intravenous therapy, the uses of... |
 |
Diagnosis and Treatment of Hepatocellular Carcinoma by Tito Livraghi (Editor), Masatoshi Makuuchi (Editor), Luigi Buscarini (Editor) The book is edited by a multidisciplinary team, with an international group of contributors. After discussing the basic and clinical aspects of HCC the main focus of the book is on diagnosis and therapy. The book is both authoritative and practical, providing expert guidance on the various techniques used in diagnosis, such as ultrasound, CT and MRI and the appropriate therapeutic options, for example, surgical resection, transcatheter therapies and radiofrequency ablation. It is fully illustrated throughout in both colour and black and white. |
|
|
5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences - 2007 DVD 03 Symposium: Large HCC (> 5cm) Chairpersons: J. Belgethi, S.A. Curley, W.C. Chapman Surgical Resection J. N. Vauthey Liver Transplantation in Patients with and without Chronic Liver Disease P. Neuhaus Nonsurgical Treatment T. W T. Leung |
|
Spontaneous regression of hepatocellular carcinoma: potential promise for the future.: An article from: Southern Medical Journal by Harsha Gadadhar Vardhana (Author), Mukta Panda (Author) This digital document is an article from Southern Medical Journal, published by Thomson Gale on February 1, 2007. The length of the article is 541 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Spontaneous regression of hepatocellular carcinoma: potential promise for the future. Author: Harsha Gadadhar Vardhana Publication: Southern Medical Journal (Magazine/Journal) Date: February 1, 2007 Publisher: Thomson Gale Volume: 100 Issue: 2 Page: 223(2) Distributed by Thomson... | |
|
|
5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences 2007- DVD 02 Also With: The University of Texas - MD Anderson Cancer Center (Host) Symposium: Early HCC (< 2cm) Chairpersons: M. Makuuchi, C. Charnsangavej, K.Ahrar Imaging of Dysplastic Nodules and Early HCC B. Taouli,MD Dysplastic Nodules vs. Early HCC: The Eastern Perspective M. Kojiro, MD Dysplastic Nodules vs. Early HCC: The Western Perspective G.Y. Lauwers, MD Therapy: Resection, Radiofrequency Ablation, or Transplantation T. Takayama, MD |
![p53 Mutations in hepatocellular carcinoma patients in Egypt [An article from: International Journal of Hygiene and Environmental Health]](http://ecx.images-amazon.com/images/I/51D8PA7D0TL._SL160_.jpg) |
p53 Mutations in hepatocellular carcinoma patients in Egypt [An article from: International Journal of Hygiene and Environmental Health] by S.A. El-Kafrawy (Author), M. Abdel-Hamid (Author), M. El-Daly (Author), Nada (Author) This digital document is a journal article from International Journal of Hygiene and Environmental Health, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: The p53 gene plays a major role in hepatocellular carcinoma (HCC). Acquired mutations may provide clues to etiology, as some carcinogenic agents are associated with specific genetic changes in p53. Our aim was to analyze the spectrum of p53 mutations in tumor tissues from subjects with HCC in Egypt, where there is a rising incidence of HCC due to hepatitis C virus (HCV). We collected tumor tissues from 41 subjects with HCC diagnosed at the National Cancer Institute of Cairo... |
|
Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine.( alkaloids)(Clinical report): An ... Journal of Phytotherapy & Phytopharmacology by X.-N. Wang (Author), X. Han (Author), L.-N. Xu (Author), L.-H. Yin (Author), Y.-W. Xu (Author), Y. Qi (Author), J.-Y. Peng (Author) This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on December 1, 2008. The length of the article is 3665 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine.( alkaloids)(Clinical report) Author: X.-N. Wang Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Magazine/Journal) Date: December 1, 2008 Publisher: Urban & Fischer Verlag Volume: 15 Issue:... |
| © 2009 BrightSurf.com |